Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Timber Pharmaceuticals, Inc. (TMBR)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.3166+0.0009 (+0.29%)
At close: 04:00PM EST
0.3260 +0.01 (+2.97%)
After hours: 04:26PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3157
Open0.3165
Bid0.3157 x 800
Ask0.3166 x 1400
Day's Range0.3007 - 0.3279
52 Week Range0.3007 - 3.6500
Volume1,164,785
Avg. Volume3,188,046
Market Cap20.198M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

    Virtual Conference on January 10-13, 2022 BASKING RIDGE, NJ, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that John Koconis, Chairman and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held

  • GlobeNewswire

    Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

    Call to be held on Monday, November 22nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will host a conference call for investors and shareholders to discuss the positive topline results from its recently completed Phase 2

  • GlobeNewswire

    Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results

    Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third q

Advertisement
Advertisement